Lyme Disease Testing Market

Lyme Disease Testing Market Analysis and Forecast by Fact.MR

• The global Lyme disease testing market is estimated at US$ 12.5 billion in 2025, forecast to expand at a CAGR of 8.3% to reach US$ 30.0 billion by 2036.
• Lyme disease testing encompasses serological assays, western blot confirmatory tests, molecular diagnostic kits, and rapid point of care tests designed to detect Borrelia burgdorferi infection.
• Demand is shaped by rising tick borne disease incidence, evolving diagnostic algorithms including modified two tier testing, and increasing clinical awareness of early stage disease presentation across endemic regions.

Summary of Lyme Disease Testing Market

• Market Snapshot
  • In 2025, the global Lyme Disease Testing Market was valued at approximately USD 12.5 billion.
  • The market is estimated to reach USD 13.5 billion in 2026 and is projected to attain USD 30 billion by 2036.
  • The lyme disease testing market is likely to expand at a CAGR of 8.3% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 16.5 billion between 2026 and 2036.
  • Serological Testing Kits account for 46% of product type share in 2026.
  • France (8.5%) and Mexico (8.2%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Rising Lyme disease incidence across temperate regions in North America and Europe sustains demand for serological and molecular diagnostic tests.
  • Adoption of modified two tier testing algorithms replacing traditional western blot confirmation is driving assay reformulation and new product development.
  • Growing clinical awareness of early stage Lyme disease presentation is increasing test ordering rates across primary care and emergency settings.
  • Expanding institutional procurement and healthcare infrastructure development across emerging economies is increasing demand.
  • Product innovation and format diversification are broadening market access across clinical and non clinical channels.
• Product and Segment View
  • Serological Testing Kits account for 46% of the product type segment in 2026, supported by established clinical use and procurement patterns.
  • Early Stage Lyme Disease accounts for 48% of the application segment in 2026.
  • Key segmentation includes:
    • Product Type: Serological Testing Kits, Western Blot Assays, Molecular Diagnostic Kits, Rapid Diagnostic Tests
    • Application: Early Stage Lyme Disease, Late Stage Lyme Disease, Screening Programs, Confirmatory Testing
    • End Use: Diagnostic Laboratories, Hospitals, Research Institutes, Point of Care Settings
    • Technology: Immunoassay Technology, Molecular Diagnostic Technology, Lateral Flow Technology, Multiplex Testing Technology
    • Formulation: Liquid Reagents, Lyophilized Reagents, Ready to Use Kits, Control Materials
    • Distribution Channel: Direct Sales, Distributors, Online Sales
  • These systems enable:
    • Accurate detection of Borrelia burgdorferi antibodies through two tier serological testing algorithms
    • Molecular confirmation of active infection through PCR based nucleic acid amplification
    • Rapid point of care screening enabling same visit clinical decision making in primary care settings
• Geography and Competitive Outlook
  • France leads growth at 8.5%, supported by high Lyme disease incidence, national surveillance programs, and expanding laboratory testing capacity.
  • North America remains a major market with the USA at 7.6%, driven by endemic transmission zones, modified two tier testing adoption, and growing point of care demand.
  • European markets show steady growth, with Germany at 7.3% supported by tick borne disease surveillance and laboratory diagnostic infrastructure.
  • Key companies include DiaSorin S.p.A, BIOMERIEUX, Oxford Immunotec, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and T2 Biosystems, IGeneX, Gold Standard Diagnostics, ZEUS Scientific, Trinity Biotech.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The Lyme disease testing market is being reshaped by the transition from traditional two tier algorithms to modified protocols and next generation assays that combine serological and cellular immunity markers. The diagnostic gap in early stage disease remains the largest unmet clinical need, and companies investing in T cell response detection and multiplex platforms are positioned to capture premium pricing. Geographic expansion into newly endemic regions is creating incremental demand beyond traditional markets.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising Lyme disease incidence across temperate regions in North America and Europe sustains demand for serological and molecular diagnostic tests.
• Adoption of modified two tier testing algorithms replacing traditional western blot confirmation is driving assay reformulation and new product development.
• Growing clinical awareness of early stage Lyme disease presentation is increasing test ordering rates across primary care and emergency settings.

Key Market Constraints

• Diagnostic sensitivity limitations in early stage infection, before antibody seroconversion, reduce the clinical utility of serological tests in the first weeks after tick exposure.
• Reimbursement variability across payers and geographies creates uneven market access for advanced molecular and multiplex testing platforms.
• False positive concerns with serological assays in endemic areas where background seropositivity rates are elevated reduce test specificity perception.

Key Opportunity Areas

• T cell based diagnostic approaches combining cellular and humoral immunity markers offer potential for improved early stage detection sensitivity.
• Point of care rapid tests are expanding testing beyond reference laboratories into primary care, urgent care, and field settings.
• Multiplex tick borne disease panels that simultaneously test for Lyme, anaplasmosis, babesiosis, and other co infections are increasing per test revenue.

Segment-wise Analysis of the Lyme Disease Testing Market

• Serological Testing Kits hold 46% of the respective segment in 2026.
• Early Stage Lyme Disease hold 48% of the respective segment in 2026.
• Diagnostic Laboratories hold 55% of the respective segment in 2026.

Which Product Type Segment Leads the Lyme Disease Testing Market?

Serological testing kits are estimated to account for 46% of the product type segment in 2026. Enzyme immunoassay and chemiluminescent immunoassay formats remain the primary first tier screening tools in Lyme disease diagnostic algorithms, supported by established laboratory workflow integration and regulatory clearance across major markets.

The segment benefits from high test volume driven by clinical ordering patterns in endemic regions. Modified two tier testing protocols that replace western blot with a second enzyme immunoassay are increasing serological test utilization while simplifying confirmatory workflows.

Which Application Segment Leads the Lyme Disease Testing Market?

Early stage Lyme disease detection accounts for 48% of the application segment in 2026. Clinical urgency to identify infection before dissemination drives the highest volume of test orders, with primary care physicians, emergency departments, and urgent care clinics generating most early stage testing demand.

The segment faces diagnostic challenges because antibody levels may not be detectable in the first two to three weeks after tick bite. This sensitivity gap is driving investment in next generation assays that incorporate cellular immunity markers and molecular detection to improve early stage diagnostic accuracy.

Which End Use Segment Leads the Lyme Disease Testing Market?

Diagnostic laboratories account for 55% of the end use segment in 2026, reflecting their central role in processing serological and molecular Lyme disease tests. Reference laboratories and hospital based clinical laboratories handle the majority of two tier testing volume, with established instrument platforms and quality assurance protocols.

Point of care settings are growing faster as rapid diagnostic tests gain clinical acceptance for same visit screening. Primary care offices and urgent care clinics in endemic regions are adopting lateral flow based rapid tests, but laboratory based testing retains the largest share due to sensitivity, specificity, and confirmatory testing requirements.

Which Product Trend is Shaping the Next Phase of Growth in the Lyme Disease Testing Market?

Multiplex tick borne disease panels are emerging as the fastest growing product category in the market. These panels simultaneously test for Lyme disease, anaplasmosis, babesiosis, ehrlichiosis, and other co infections from a single blood draw. Co infection rates in many endemic areas are clinically significant, making single disease testing insufficient for comprehensive patient management.

The shift toward multiplex testing reflects both clinical need and laboratory efficiency gains. Clinicians want comprehensive tick borne disease coverage without ordering multiple individual tests, and laboratories benefit from higher per sample revenue and streamlined workflows. As multiplex platforms gain regulatory clearance and payer reimbursement, they are moving from specialty reference laboratories into routine hospital and commercial laboratory testing menus.

Regional Outlook Across Key Markets

• France leads growth at 8.5%, supported by high Lyme disease incidence, national surveillance programs, and expanding laboratory testing capacity.
• North America remains a major market with the USA at 7.6%, driven by endemic transmission zones, modified two tier testing adoption, and growing point of care demand.
• European markets show steady growth, with Germany at 7.3% supported by tick borne disease surveillance and laboratory diagnostic infrastructure.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Lyme Disease Testing in the United States

The U.S. Lyme disease testing market is projected to grow at a CAGR of 7.6% through 2036. Demand is supported by high endemic transmission, modified two tier testing adoption, and expanding point of care screening.

• Modified two tier testing protocols are replacing traditional western blot confirmation.
• Point of care rapid tests are expanding testing access in primary care settings.
• Multiplex tick borne disease panels are gaining reimbursement coverage.

Lyme Disease Testing Demand Trends in France

The France Lyme disease testing market is projected to grow at a CAGR of 8.5% through 2036. Growth reflects high Lyme disease burden, national surveillance programs, and laboratory testing infrastructure development.

• National tick borne disease surveillance supports testing volume growth.
• Laboratory diagnostic infrastructure enables broad test access across regions.
• Clinical awareness campaigns increase test ordering rates in primary care.

Germany Lyme Disease Testing Market Growth Assessment

The Germany Lyme disease testing market is projected to grow at a CAGR of 7.3% through 2036. Demand is supported by tick borne disease surveillance programs and laboratory diagnostic infrastructure.

• Tick surveillance data supports clinical testing decisions in endemic regions.
• Laboratory networks provide broad geographic coverage for two tier testing.
• Research investment in next generation diagnostic assays supports product innovation.

United Kingdom Lyme Disease Testing Market Demand Analysis

The UK Lyme disease testing market is projected to grow at a CAGR of 7.0% through 2036. Demand is shaped by rising Lyme disease awareness, NHS diagnostic pathways, and reference laboratory testing capacity.

• NHS diagnostic pathways support standardized Lyme disease testing protocols.
• Reference laboratory capacity enables confirmatory testing across the country.
• Clinical awareness of tick borne disease is increasing test ordering rates.

Canada Lyme Disease Testing Market Opportunity Outlook

The Canada Lyme disease testing market is projected to grow at a CAGR of 6.9% through 2036. Demand reflects expanding endemic zones, public health surveillance, and laboratory testing capacity.

• Expanding endemic zones are increasing Lyme disease testing volumes.
• Public health surveillance supports clinical testing protocols.
• Laboratory capacity development supports growing diagnostic demand.

Competitive Benchmarking and Company Positioning

Lyme Disease Testing Market Analysis By Company

• DiaSorin S.p.A holds a leading position with approximately 19% share, supported by a broad product portfolio and established institutional relationships.
• BIOMERIEUX, Oxford Immunotec, Bio-Rad Laboratories, Inc. participate meaningfully across specific categories and regional channels.
• Competition is shaped by product differentiation, regulatory approvals, institutional procurement, and geographic distribution.

The competitive landscape is moderately fragmented. DiaSorin S.p.A leads through portfolio breadth and regulatory approvals. BIOMERIEUX, Oxford Immunotec, Bio-Rad Laboratories, Inc. maintain relevance across specific niches. Strategic priorities include expanding product portfolios, strengthening distribution, and investing in next generation development.

Key Companies in the Lyme Disease Testing Market

• DiaSorin S.p.A, BIOMERIEUX, Oxford Immunotec, Bio-Rad Laboratories, Inc. are among the leading players globally.
• Thermo Fisher Scientific, Inc., T2 Biosystems, IGeneX, Gold Standard Diagnostics, ZEUS Scientific, Trinity Biotech hold positions across specific segments and regional markets.

Recent Industry Developments

• DiaSorin S.p.A (with QIAGEN) : Product Submission / Early Detection Assay (2025)
  • DiaSorin continued regulatory engagement for FDA review of LIAISON LymeDetect, a next generation assay combining serological and T cell immunity detection for improved early stage Lyme disease diagnosis. The assay demonstrated 74% sensitivity within 21 days of infection versus 49% for established methods in clinical studies.
• T2 Biosystems : Technology Development / Rapid Molecular Detection (2025)
  • T2 Biosystems continued development of its rapid molecular diagnostic platform for tick borne disease detection, leveraging T2 Magnetic Resonance technology for direct pathogen detection without blood culture.
• Bio-Rad Laboratories, Inc. : Portfolio Expansion / Immunoassay Platform Updates (2025)
  • Bio-Rad continued to expand its Lyme disease serological testing portfolio with updated immunoassay configurations supporting modified two tier testing algorithm adoption across clinical laboratory networks.

Leading Companies Shaping the Lyme Disease Testing Market

• DiaSorin S.p.A
• BIOMERIEUX
• Oxford Immunotec
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• T2 Biosystems
• IGeneX
• Gold Standard Diagnostics
• ZEUS Scientific
• Trinity Biotech

Sources and Research References

• DiaSorin S.p.A. LIAISON LymeDetect regulatory submission and clinical data.
• Bio-Rad Laboratories, Inc. Lyme disease immunoassay portfolio updates.
• U.S. Centers for Disease Control and Prevention. Lyme disease surveillance and diagnostic algorithm guidance.
• World Health Organization. Tick borne disease epidemiology and diagnostic standards.
• Primary interviews with diagnostic laboratory directors, infectious disease physicians, test manufacturers, and public health officials.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Lyme disease testing market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product type leads the market by 2026?
• Which application segment accounts for the highest demand?
• What factors are driving demand globally?
• How is modified two tier testing influencing the market?
• Why is France the fastest growing market?
• Which countries show the fastest growth through 2036?
• Who are the key companies?
• How does Fact.MR estimate the forecast?

Lyme Disease Testing Market Definition

The Lyme disease testing market covers serological assays, western blot confirmatory tests, molecular diagnostic kits, and rapid point of care tests designed to detect Borrelia burgdorferi infection. It includes enzyme immunoassay, chemiluminescent immunoassay, PCR based, and lateral flow platforms used across diagnostic laboratories, hospitals, research institutes, and point of care settings for early stage detection, late stage diagnosis, screening programs, and confirmatory testing.

Lyme Disease Testing Market Inclusions

• Global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, formulation, distribution channel, and region.
• Regional demand analysis based on Lyme disease incidence, tick surveillance data, diagnostic algorithm adoption, and laboratory infrastructure.
• Pricing analysis across standard serological, molecular, and rapid test categories.
• Competitive landscape including product portfolios, regulatory clearances, and distribution strategies.

Lyme Disease Testing Market Exclusions

• General purpose immunoassay platforms not specifically configured for Lyme disease testing.
• Tick identification and environmental surveillance equipment without diagnostic function.
• Veterinary Lyme disease testing products not intended for human clinical use.
• Research use only reagents not cleared for clinical diagnostic applications.

Lyme Disease Testing Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 100+ secondary sources and benchmarks 50+ company product portfolios.
• Market sizing covers 30+ countries through a demand side model, supported by top down validation.
• Key inputs include disease incidence data, institutional procurement patterns, regulatory frameworks, and product pricing trends.
• The model cross checks demand with shipment volumes, pricing trends, channel mix, and product launch timelines.
• Primary validation includes 25+ interviews across manufacturers, distributors, healthcare providers, and institutional procurement officers.
• Final estimates go through supply validation, trade flow checks, and sensitivity testing.